Compare NPKI & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | CMPS |
|---|---|---|
| Founded | 1932 | 2020 |
| Country | United States | United Kingdom |
| Employees | 510 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | NPKI | CMPS |
|---|---|---|
| Price | $14.27 | $13.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $14.17 | ★ $25.38 |
| AVG Volume (30 Days) | 1.2M | ★ 3.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.39 | N/A |
| Revenue Next Year | $11.70 | N/A |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.17 | $3.25 |
| 52 Week High | $16.50 | $15.40 |
| Indicator | NPKI | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 58.42 |
| Support Level | $13.70 | $5.57 |
| Resistance Level | $15.28 | $14.76 |
| Average True Range (ATR) | 0.77 | 0.96 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 13.16 | 58.12 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom. It generates maximum revenue from United States.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.